Weiss Multi-Strategy Advisers’s Aratana Therapeutics, Inc. PETX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-10,000	Closed	-$178K	–	562
2014 Q4	$178K	Buy	+10,000	New	+$125K	0.01%	381

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OAC

OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Weiss Multi-Strategy Advisers's PETX Position: Q2 2019 in Review

Weiss Multi-Strategy Advisers sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 175,000 shares — an estimated $630K sold.

Weiss Multi-Strategy Advisers first reported a position in PETX in Q1 2014 and held it in 21 quarters. The position peaked at $1.36M in Q2 2015. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

Weiss Multi-Strategy Advisers reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 175,000 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $630K.
Weiss Multi-Strategy Advisers first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 21 quarters.
Weiss Multi-Strategy Advisers's Aratana Therapeutics, Inc. position peaked at $1.36M in Q2 2015.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.